Literature DB >> 1611952

Local immunity and metastasis of colorectal carcinoma.

Y Kubota1, K Sunouchi, M Ono, T Sawada, T Muto.   

Abstract

The subsets of tumor-infiltrating lymphocytes (TIL) and prostaglandin (PG) E2 were measured in the resected tissues of 32 colorectal cancers without metastasis and 14 with metastasis in order to investigate the local immunity in metastasis of colorectal carcinoma. Subsets of TIL (Leu 1, Leu 2a, Leu 3a, Leu 10, Leu 11b, IL-2 receptor) were detected by immunohistochemical staining of frozen tissues. The number of positive cells was counted and expressed as number positive per 250 x 250 microns 2. The numbers of T cells (Leu 1) and natural killer cells (Leu 11b) were larger in early cancers and decreased in parallel with the presence of metastasis (control [n = 9]: 89 +/- 28, 6 +/- 4; early cancers [n = 9]: 269 +/- 112*, 76 +/- 56*; advanced cancers without metastasis [n = 11]: 182 +/- 80*, 56 +/- 59*; advanced cancers with metastasis [n = 11]: 76 +/- 42*, 26 +/- 21; values are mean +/- SD; * P less than 0.05, ANOVA). The level of PG E2 from the draining vein (V) measured by radioimmunoassay was higher than that from the feeding artery (A) (119.1 +/- 14.3 vs. 15.4 +/- 1.9 pg/ml; P less than 0.001). The PG E2 V/A ratio of cancers with metastasis was significantly higher than that of those without metastasis (13.2 +/- 2.4 vs. 5.6 +/- 0.8; P less than 0.001). TIL was decreased in parallel with the increase of PG E2 V/A ratio. We conclude that TIL and PG E2 may play an important role in metastasis of colorectal carcinoma and that PG E2 has an adverse effect in suppressing local immunity and enhancing metastasis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611952     DOI: 10.1007/bf02053754

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  9 in total

1.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.

Authors:  K Shiraki; N Tsuji; T Shioda; K J Isselbacher; H Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 2.  Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk elderly patients?

Authors:  M I Koutsos; S J Shiff; B Rigas
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

Review 3.  The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1996-09       Impact factor: 6.968

4.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 5.  Eicosanoids and the immunology of cancer.

Authors:  M R Young
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

6.  Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity.

Authors:  Tuanjie Li; Shuhong Yi; Wei Liu; Changchang Jia; Guoying Wang; Xuefeng Hua; Yan Tai; Qi Zhang; Guihua Chen
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

7.  Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas.

Authors:  P A Jackson; M A Green; C G Marks; R J King; R Hubbard; M G Cook
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

8.  PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF‑κB in tumour metastases of colon carcinoma.

Authors:  Jie-Qiong Wang; Yi Tang; Qing-Shu Li; Ming Xiao; Ming Li; Yong-Tao Sheng; Yi Yang; Ya-Lan Wang
Journal:  Oncol Rep       Date:  2019-03-07       Impact factor: 3.906

9.  Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells.

Authors:  Quanxin Wang; Yoshiyuki Takei; Osamu Kobayashi; Taro Osada; Sumio Watanabe
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.